ACADIA Announces Management Appointments in Business Development and Research and Development
SAN DIEGO, March 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the appointments of Brian Lundstrom to Senior Vice President, Business Development, Daniel P. van Kammen, M.D., Ph.D., to Vice President, Clinical Development, and Douglas W. Bonhaus, Ph.D., to Vice President, Biosciences.
"These appointments serve to further strengthen our organization in key areas that will drive success for ACADIA as we continue to mature our clinical pipeline and position selected programs for strategic commercial alliances," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. "With these additions, we not only have enhanced our partnering capabilities, but also have added additional cutting edge expertise in both our clinical and pre-clinical organizations."
Brian Lundstrom, Senior Vice President, Business Development
Mr. Lundstrom has joined ACADIA as Senior Vice President, Business Development. Mr. Lundstrom was previously Vice President, Business Development at Genzyme Corporation where he led the integration and outlicensing of assets from his previous employer, SangStat Medical Corporation, until the sale of that company to Genzyme. Mr. Lundstrom has broad industry experience and a proven track record in business development, having executed over 40 deals on discovery technologies, clinical-stage product candidates and marketed products in his career. Mr. Lundstrom also has held senior business, clinical, and product development positions at Oxford LycoSciences (now UCB Bioproducts) and Novo Nordisk. Mr. Lundstrom has a Master of Science in Chemical Engineering with a biotechnology specialization from the Danish Technology University and an MBA equivalent degree in International Business and Finance from Copenhagen Business School and Seattle University.
Daniel P. van Kammen, M.D., Ph.D., Vice President, Clinical Development
Dr. van Kammen has joined ACADIA as Vice President, Clinical Development. Dr. van Kammen joined ACADIA from Aventis, where he served as Head of CNS, Clinical Discovery and Human Pharmacology and was co-responsible for Aventis' schizophrenia strategy. Prior to Aventis, he was Senior Director, Global Development, at J&J Pharmaceutical Research and Development. Dr. van Kammen has extensive experience in CNS strategy and program development and has directed a wide range of CNS clinical programs, including those in the fields of schizophrenia and sleep disorders. Dr. van Kammen received a Ph.D. in Pharmacology from the University of Utrecht in the Netherlands. He holds an M.D. from the University of Utrecht Medical School and completed his residency in psychiatry at Johns Hopkins Hospital.
Douglas W. Bonhaus, Ph.D., Vice President, Biosciences
Dr. Bonhaus has joined ACADIA as Vice President, Biosciences. Dr. Bonhaus joins ACADIA from Roche, where he was Department Head. Dr. Bonhaus has over 13 years of experience in the biopharmaceutical industry, which includes establishing discipline-based research groups and leading drug discovery and development programs for CNS disorders, particularly in the areas of neuropsychiatric disorders, neuropathic pain, and migraine. He also served for four years as Research Assistant Professor in the Department of Medicine, Neurology Division, at Duke University. Dr. Bonhaus received a Ph.D. degree in Pharmacology and Toxicology from the University of Arizona and a Bachelor of Science degree in Physiology from Michigan State University.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA's corporate headquarters and biology research facilities are located in San Diego, California and its chemistry research facilities are located near Copenhagen, Denmark.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of our drug discovery and drug development programs and our clinical trials, the potential for new collaborations, and our future results. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development and commercialization and forming partnerships and alliances. For a discussion of these and other factors, please refer to ACADIA's registration statement on Form S-1 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer